Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ximelagatran in orthopaedic surgery.

Bengt Eriksson1

  • 1Department of Orthopedics, Sahlgrenska University Hospital/Ostra, SE-41685 Gothenburg, Sweden. b.eriksson@orthop.gu.se

Pathophysiology of Haemostasis and Thrombosis
|April 7, 2005
PubMed
Summary

Ximelagatran, a new oral anticoagulant, effectively prevents venous thromboembolism (VTE) in orthopedic surgery patients. Studies show it is comparable or superior to low-molecular-weight heparin, with optimal dosing and timing crucial for balancing efficacy and bleeding risk.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Coordinated early immune response in the lungs is required for effective control of SARS-CoV-2 replication.

Nature communications·2025
Same author

Biochemical and hematological reference intervals in rhesus and cynomolgus macaques and implications for vaccine and drug development.

Lab animal·2025
Same author

Author Correction: Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses.

Nature communications·2023
Same author

Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses.

Nature communications·2023
Same author

Single cell transcriptomics of primate sensory neurons identifies cell types associated with chronic pain.

Nature communications·2021
Same author

Route of Vaccine Administration Alters Antigen Trafficking but Not Innate or Adaptive Immunity.

Cell reports·2020

Area of Science:

  • Pharmacology
  • Thrombosis Research
  • Orthopedic Surgery

Background:

  • Ximelagatran is the first new oral anticoagulant in nearly 60 years, offering an alternative to warfarin.
  • Venous thromboembolism (VTE) remains a significant risk for patients undergoing orthopedic surgery.
  • Low-molecular-weight heparins (LMWHs) are standard prophylaxis, but new agents are being investigated.

Purpose of the Study:

  • To evaluate the efficacy and safety of subcutaneous (s.c.) melagatran followed by oral ximelagatran for VTE prevention in orthopedic surgery.
  • To compare melagatran/ximelagatran regimens with LMWHs (dalteparin, enoxaparin).
  • To determine the optimal timing and dosage of melagatran for VTE prophylaxis.

Main Methods:

  • The METHRO (MElagatran THRomboprophylaxis in Orthopaedic surgery) and EXPRESS (EXpanded PRophylaxis Evaluation Surgery Study) trials were conducted.

Related Experiment Videos

  • Patients undergoing hip or knee replacement received s.c. melagatran followed by oral ximelagatran.
  • Different dosing strategies and initiation times (pre-operative vs. post-operative) were assessed and compared to LMWHs.

    • Main Results:

    • Highest dose melagatran/ximelagatran significantly reduced VTE compared to dalteparin in METHRO II (15.1% vs. 28.2%).
    • Post-operative initiation of melagatran/ximelagatran showed comparable efficacy to pre-operative enoxaparin in METHRO III.
    • The EXPRESS study found a melagatran/ximelagatran regimen significantly more effective than enoxaparin (20.3% vs. 26.6%), with comparable severe bleeding rates.

    Conclusions:

    • Melagatran/ximelagatran demonstrates comparable or superior efficacy to LMWHs for VTE prevention in orthopedic surgery.
    • Early post-operative initiation of melagatran/ximelagatran (4-8 hours) improved efficacy.
    • Optimal dosing and timing are critical for maximizing the benefit-risk profile of melagatran/ximelagatran.